EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY

Month: October 2024

Apellis Present Pivotal VALIANT Results at Kidney Week Highlighting Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN

October 30, 2024

WALTHAM, Mass. October 26, 2024 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® today announced that positive results from the Phase 3 VALIANT

Read »

Dr. Falk Pharma acquires spinout Kynos Therapeutics to develop its novel KMO inhibitors for acute pancreatitis

October 29, 2024

29 October 2024, Dr. Falk Pharma GmbH today announced completion of the acquisition of Kynos Therapeutics Ltd., a clinical stage biopharmaceutical company focusing on the

Read »

Topas Therapeutics Announces Positive Topline Results from Phase 2a Trial Evaluating TPM502 in Patients with Celiac Disease

October 16, 2024

Hamburg, Germany, October 15th, 2024 – Topas Therapeutics today announced positive topline results from its Phase 2a trial evaluating lead candidate, TPM502, in patients with

Read »

EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY

Month: October 2024

Apellis Present Pivotal VALIANT Results at Kidney Week Highlighting Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN

Dr. Falk Pharma acquires spinout Kynos Therapeutics to develop its novel KMO inhibitors for acute pancreatitis

Topas Therapeutics Announces Positive Topline Results from Phase 2a Trial Evaluating TPM502 in Patients with Celiac Disease

Categories

Archives